Genmab — November 2019
-
NextCure stiger beskedne 183% efter at have været oppe med 221% pga af data fra et fase 1 studie: Results from the just-published abstract showed one complete response (41 weeks to date), one partial response (14 weeks to date) and a disease control rate (DCR) of 71% (n=5/7) in patients with non-small cell lung cancer (NSCLC) who received NC318 alone. Response data from 11 additional patients will be presented on Saturday. Bare vent til kl 15 i morgen når cd3xcd20 kommer på gaden
-
Hmm - NextCures marked cap er efter stigningen 1,9 millarder USD. Så biksen er ikke så stor....
-
Det plejer nu at være mikroputter som stiger så meget på fase 1 forsøg-
-
Genmab har en sensationel pipeline siger JvW til Børsen ""Jeg kan lide det, og jeg mener virkeligt at jeg kan gøre en forskel. Holdet vokser og bliver bedre og bedre, og vi har en sensationel pipeline, som basalt set er på størrelse med hvad en mellemstor medicinalvirksomhed med 10.000 ansatte har. Det giver mig enorm energi," siger Jan van de Winkel."
-
Servicemeddelelse: Vi arbejder på websiden i de kommende timer. Den kan derfor være nede eller se mærkelig ud. Beklager meget.
-
https://www.curetoday.com/articles/investigational-therapy-delivers-treatment-to-patients-with-multiple-myeloma-in-two-doses Et stof vi skal have på radaren.
-
Tak Solsen. Lidt om Cellectar biosciences https://www.investing.com/analysis/cellectar-biosciences-(clrb)-pdc-delivery-platform-may-advance-treatment-200175567
-
God morgen.
-
God morgen
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind